Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Karaya gum + acacia + tragacanth is a legacy combination **allergenic extract** composed of three plant-derived gum allergens: karaya gum, acacia gum arabic, and tragacanth. It was used as a therapeutic allergen immunotherapy product for patients with documented sensitization to these vegetable gum allergens, with the intent of hyposensitization through repeated parenteral exposure to the relevant allergenic materials. Mechanistically, it does not act through a single molecular target; rather, as an allergen extract immunotherapy, it is intended to modulate pathologic allergen-specific immune responses and reduce clinical reactivity to the included gum allergens over time. Available context suggests a multi-dose injectable biologic/allergenic extract product with an inactive FDA NDC listing, and no clearly identifiable contemporary sponsor, implying a compounded, historical, or discontinued marketed allergenic extract rather than an active modern development program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on karaya gum + acacia + tragacanth.